Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 3 Multivariable-adjusted regression of standardized hemoglobin A1c and adverse cardiovascular outcomes

From: Hemoglobin A1c stratifies risk of adverse cardiovascular outcomes in prostate cancer survivors in the UK Biobank: a cohort study

Variable

sHR (95% CI)1

P-Value

Hemoglobin A1c (%), per 1-SD

1.16 (1.04–1.29)

0.007

Age (years), per 1-SD

1.20 (1.02–1.41)

0.032

White Race

1.22 (0.55–2.69)

0.630

Body Mass Index (kg/m2), per 1-SD

1.14 (0.98–1.33)

0.087

Smoking History

1.12 (0.82–1.53)

0.460

Systolic Blood Pressure (mm Hg), per 1-SD

1.03 (0.88–1.21)

0.740

Total Cholesterol (mg/dL), per 1-SD

1.17 (1.01–1.36)

0.043

High-Density Lipoprotein Cholesterol (mg/dL), per 1-SD

0.72 (0.59–0.88)

0.001

eGFR2 (mL/min/1.73 m2), per 1-SD

0.85 (0.75–0.97)

0.013

Blood Pressure Medication Use

1.13 (0.81–1.57)

0.480

Cholesterol Medication Use

1.12 (0.76–1.63)

0.570

Insulin Use

2.78 (1.13–6.85)

0.026

  1. 1 Estimated by competing-risk regression, while accounting for non-cardiovascular death; sHR = subdistribution hazard ratio; CI = confidence interval
  2. 2 eGFR = estimated glomerular filtration rate
Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us